Intermediate hepatocellular carcinoma: How to choose the best treatment modality? - Wikidata - awgldk - TriplyDB

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

http://www.wikidata.org/entity/Q35626764

about

Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).The Ethanol Supernatant Extracts of Liushenwan Could Alleviate Nanodiethylnitrosamine-Induced Liver Cancer in Mice

P2860

Q37601179-1F0CEF75-393C-4885-BAC2-9D0B0A39823F Q38635603-714599FC-973F-400B-A883-9282ADA8FE52 Q38652404-62C4F980-8AD4-4AEB-B0C4-2C210427B233 Q42523379-945F1518-178B-4D4C-B0AC-FD8A8CD07C6E Q57821237-C73BAC90-0315-4A56-AFEE-1B8FD4C45EA3

P2860

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

http://www.wikidata.org/entity/Q35626764

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

@ast

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

@en

type

label

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

@ast

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

@en

prefLabel

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

@ast

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

@en

P1433

Q35626764-72D675B3-F204-405F-923B-D7B95038C0EB

P1476

Q35626764-36539FBE-7336-4A59-923E-B8A644DFDE03

P2093

Q35626764-526367CC-0D8C-493B-8C5D-A615449C9A6D

P2860

Q35626764-01666662-A0F9-444F-B934-233CB087FE11

Q35626764-028FC020-0DCA-45B4-8AE6-554B5822A73D

Q35626764-07AFF8AD-5743-4F21-B612-64CE8C4CD0CB

Q35626764-09A4BD9B-D209-47E2-AB67-8D07EA76A075

Q35626764-0D09736B-965A-49C2-B951-FD15912F273B

Q35626764-0E8FD8F5-E70D-493F-86A3-7257DD5CD18B

Q35626764-202164A7-300A-4D57-B721-725C7C3200AF

Q35626764-2626FA4B-B90B-4A9F-BC49-3E09A870FC4B

Q35626764-2DC6ACD4-ACD3-4338-B9BD-31AEB9CD927F

Q35626764-2F557ACA-48B3-483A-A660-E824E3BF9D86

P304

Q35626764-D7FDBCD1-BAEA-4020-A2CF-099990BBCA92

P31

Q35626764-4939AB07-08C7-4306-BDE1-D6E974E19E8C

P356

Q35626764-CD949B19-D999-4AEC-AABF-37638724D5C3

P433

Q35626764-D14BF866-32D2-431C-936A-00A6730E13FC

P478

Q35626764-10B2A004-5439-47D2-96D4-8B6ACECDE64D

P50

Q35626764-AA01612D-6099-4C97-9992-5095E5568C35

P577

Q35626764-ADA20571-87A1-4823-A9D8-92FF224136E3

P5875

Q35626764-A1B6590D-75C1-4C19-A0DB-C3DD347575C2

P698

Q35626764-68BA4D36-76F7-41B2-8219-134C666231B4

P932

Q35626764-A5CFF1A2-2035-4CD9-A77A-3E21EF3D1FDB

P356

P1433

World journal of hepatology

P1476

Intermediate hepatocellular carcinoma: How to choose the best treatment modality?

@en

P2093

Raffaella Tortora

http://www.w3.org/2001/XMLSchema#string

P2860

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Prognosis of hepatocellular carcinoma: the BCLC staging classification

Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.

Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization.

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

TACE combined with PEI versus TACE alone in the treatment of HCC: a meta-analysis.

Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.

Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis

P304

1184-1191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4254/WJH.V7.I9.1184

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Giovan G Di Costanzo

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277409610

http://www.w3.org/2001/XMLSchema#string

P698

26019734

http://www.w3.org/2001/XMLSchema#string

P932

4438493

http://www.w3.org/2001/XMLSchema#string